2024/2025

The financial year in brief

The year can be summarized by record-breaking order bookings, a continued positive trend for secure communications and progress in the transition to selling medical diagnostic imaging as a service. However, the most important thing to note is that our customers remain satisfied.

Customer satisfaction led the way

Satisfied customers, a good corporate culture, and long-term investments in developing services and products for cybersecurity in society and for increased efficiency in healthcare have led to success for Sectra through the years—and 2024/2025 fiscal year was no different.

We continued to top the 2024 Best in KLAS customer satisfaction surveys, both in new categories and segments and in those we have won for several years in a row. This provides external proof that we have the highest levels of customer satisfaction.

Succeeding in a time of change — customer satisfaction, innovation and a long-term approach

Unique trust from customers

According to a recent report, 2025 PACS Report from KLAS Research, 100% of the healthcare customers surveyed at major hospitals in the US said that they would purchase from Sectra again—a figure that no other medical diagnostic imaging (PACS) supplier was even close to reaching.

In the long term, satisfied customers and satisfied shareholders go hand in hand. High customer satisfaction is the pillar of our success in all of our operations and a clear indication of the value we create for customers and, subsequently, for our owners as well.

Low churn bodes well for the future

More than 60% of Sectra’s sales comprise recurring revenue from long-term customer contracts, a share that is growing due to an ongoing transition to service sales. We have an extremely small share of customers who are leaving us – the churn rate of recurring revenue is as low as 0.6%.

The secret behind the high level of customer satisfaction is a strong corporate culture, clearly focused on customer value and employees who are passionate about making a difference.

Highlights 2024/2025 fiscal year
Highlights 2024/2025 fiscal year
  • Major, long-term customer contracts led to historically high levels of contracted order bookings. Sectra secured some of its largest contracts ever, including its largest to date—a contract pertaining to a cloud solution for 150 Canadian hospitals in the province of Québec.
  • More customers deployed the Sectra One subscription service, often delivered as a cloud service, resulting in increased recurring revenue. The transition to the cloud is progressing rapidly. Cloud-based services accounted for 20% of the operating area’s revenue.
  • Continued growth in the US. A survey showed that Sectra was the most chosen vendor by US healthcare providers in the past two years. [1] Sectra was considered as a choice in half of the approximately 80 PACS procurements reviewed. Out of these, we were chosen as a supplier in approximately half—in other words, Sectra won more than 25% of all procurements. This is significantly more than any other supplier.
  • A growing number of healthcare providers around the world chose Sectra, and sales increased in all geographic markets.
  • Sectra strengthened its position in the digital pathology market through orders from hospitals in countries including Canada, France, Norway, Sweden and the US.

[1] Source: KLAS Research database for January 2023 to January 2025.

  • Successful launch of Sectra’s new genomics module in collaboration with the University of Pennsylvania Health System in the US. The module is used to successfully streamline management of the analyses performed in precision medicine, one of the fastest growing areas in diagnostics.
  • The use of Sectra’s cloud service for medical education continued to grow, especially for training radiologic technologists. The University of Hartford in the US is one of the new customers that ordered Sectra’s training platform.
  • Increased use of Sectra’s services for orthopaedics. Several customers who purchased Sectra One chose to use the orthopaedics module to save time and increase patient value.
  • Sectra’s research activities generated important new insights and tools to add value to healthcare, such as better feedback on AI results and monitoring AI performance.
  • Many countries are increasing their investments in defense and public security. Sectra’s ability to help customers with these needs led to improved financial performance.
  • Swedish authorities and defense customers in Europe placed orders for the further development and serial deliveries of the Tiger/S mobile encryption system and network crypto devices.
  • Agreements were entered into with several new customers in critical infrastructure for consulting and security monitoring.
  • A settlement was reached in a patent dispute in the US regarding Sectra’s patented technology for secure communication. The settlement had a positive non-recurring effect of SEK 110 million on the financial outcome for the fiscal year.
  • Delivery of solution to the Swedish Prison and Probation Service for secure access to information The solution will streamline the customer’s daily operations and provide inmates with controlled, secure access to digital services and information.

Customers ordered the newly developed
stationary phone in the Sectra Tiger/S product family
that allows multiple people to participate
in a secure call at once.

  • Our ability to make our customers successful, which is one of our fundamental strategies, enables us to grow.
  • Internal and external measurements show that Sectra is an equal opportunity workplace with satisfied employees and a strong culture.
  • All financial goals have been met.

 

 

Sectra remains top-ranked
among Sweden’s best employers
in Universum’s annual survey

A selection of financial performance measures

The Group’s order bookings, sales and operating profit exceeded previous records. With a strong financial position, positive cash flows and a significant share of recurring revenue, we are well equipped for the future.

* Figures include a positive effect of SEK 110 million from a non-recurring patent settlement.
** Proposal to the 2025 Annual General Meeting

3,240

Net sales
SEK million

723

Operating profit*
SEK million

8,706

Order bookings
SEK million

4.79

Cash flow per share
SEK

2.92

Earnings per share*
SEK

2.10

Ordinary dividend 1.10 and
extra dividend 1.00 per share**
SEK

2025 Capital Markets Day – focus medical IT

Let our management provide you with insight into:

  • Our corporate culture
  • The ongoing transition to services that are delivered via the cloud
  • Market opportunities
  • Strategies and focus forward

Tackling challenging and important problems in our customer environments

At Sectra, we prioritize long-term earnings performance over short-term margin increases. We take on challenging and important assignments to solve complex, meaningful problems in our customer environments – to drive us, our customers and our sectors forward. Digitalization of pathology and Genomics IT are two excellent examples.

Digitalization of pathology

Ten years have passed since we launched Sectra’s first pathology solution in Sweden, and the product area is growing internationally. Today more than 4 million cases have been diagnosed using our solution, and it is used for primary diagnostics at over 130 laboratories around the world. Our progress in pathology is an excellent example of how we tackle challenging and important problems in our customer environments.

IT support for genomics

The successful launch of our new IT support for genomics represents a major milestone during 2024/2025. The module is used to streamline management of the analyses performed in precision medicine, one of the fastest growing areas in diagnostics. Our offering strengthens Sectra’s position in integrated diagnostics for cancer care, an area where we remain one step ahead of the competition by gathering radiology, pathology and genomics to offer consolidated IT support.

Digitalization of pathology

Ten years have passed since we launched Sectra’s first pathology solution in Sweden, and the product area is growing internationally. Today more than 4 million cases have been diagnosed using our solution, and it is used for primary diagnostics at over 130 laboratories around the world. Our progress in pathology is an excellent example of how we tackle challenging and important problems in our customer environments.

IT support for genomics

The successful launch of our new IT support for genomics represents a major milestone during 2024/2025. The module is used to streamline management of the analyses performed in precision medicine, one of the fastest growing areas in diagnostics. Our offering strengthens Sectra’s position in integrated diagnostics for cancer care, an area where we remain one step ahead of the competition by gathering radiology, pathology and genomics to offer consolidated IT support.

Our long-term efforts to create value for healthcare and society, and ultimately our shareholders, are continuing to deliver results. We took major steps forward in our core areas—medical IT and cybersecurity—where we deliver solutions that improve people’s quality of life and safety all over the world.

Torbjörn Kronander

President and CEO of Sectra

Download a copy

Click on the links to download PDF versions of The 2024/2025 year in brief. The publication will be distributed to our shareholder by mail during July 2025.